LoW.K.Latest strategy in renal anemia management in peritoneal dialysis patients.Perit Dial Int2008; 28(Suppl 3): S76–80.
2.
LevinN.W., FishbaneS., CañedoF.V., ZeigS., NassarG.M., MoranJ.E.Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).Lancet2007; 370: 1415–21.
3.
CarreraF., LokC.E., de FranciscoA., LocatelliF., MannJ.F., CanaudB.Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.Nephrol Dial transplant2010; 25: 4009–17.
4.
KesslerM., Martínez–CastelaoA., SiamopoulosK.C., VillaG., SpinowitzB., DoughertyF.C.C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study.Hemodial Int2010; 14: 233–9.
5.
FliserD., KleophasW., DellannaF., WinklerR.E., BacksW., KraatzU.Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study.Curr Med res Opin2010; 26: 1083–9.
6.
CanaudB., MingardiG., BraunJ., AljamaP., KerrP.G., LocatelliF.Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.Nephrol Dial transplant2008; 23: 3654–61.
7.
DellannaF., WinklerR.E., BozkurtF., SchettlerV., GrafS., BockreissN.Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.Int J Clin Pract2011; 65: 64–72.
8.
BurkartJ., BeswickR., MoranJ.Hemoglobin levels in patients on peritoneal dialysis receiving CERA versus epoetin for anemia of chronic kidney disease (CKD): pooled analysis of two phase III trials (Abstract).Perit Dial Int2007; 27(Suppl 3): S13.
9.
BurkartJ., BeswickR., MoranJ.Safety and tolerability of CERA in chronic kidney disease (CKD) patients receiving peritoneal dialysis: pooled data from two phase III maintenance trials (Abstract).Perit Dial Int2007; 27(Suppl 3): S13.
